Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestin presented as an intrauterine system for intrauterine use. It releases hormone locally over up to five years, providing highly effective, reversible contraception and reducing heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable global distribution for this long‑acting contraceptive device.

Mirena, a levonorgestrel‑releasing intrauterine system, is employed in gynecologic practice to provide contraception and manage menstrual disorders. - Contraception: offers highly effective, reversible birth control for up to five years. - Heavy menstrual bleeding: decreases menstrual blood loss and improves anemia associated with excessive bleeding. - Endometrial hyperplasia (non‑cancerous): provides hormonal therapy to thin the endometrial lining and prevent progression.

Like all hormonal devices, Mirena may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Irregular bleeding or spotting - Absence of periods (amenorrhea) - Pelvic or abdominal pain - Headache

Serious or Rare Side Effects: - Uterine perforation - Device expulsion - Pelvic inflammatory disease - Ectopic pregnancy

Prior to insertion and during use, certain precautions should be observed to ensure safety and effectiveness. - Screen for pregnancy: ensure patient is not pregnant before insertion. - Assess uterine anatomy: confirm suitable cavity size and absence of fibroids or anomalies. - Monitor for infection: advise signs of pelvic infection and seek prompt care. - Review hormonal contraindications: avoid in women with active breast cancer or thromboembolic disorders. - Regular follow‑up: schedule check after insertion and periodic examinations. - Store at ambient temperature: keep device in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Mirena can be affected by other medicines that alter hormone metabolism.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce levonorgestrel efficacy. - Rifampicin: can lower hormone levels and increase risk of contraceptive failure.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase hormone exposure. - Antiretroviral protease inhibitors: may alter levonorgestrel metabolism. - Herbal St. John’s wort: may modestly decrease effectiveness.